Review
Single-pill combination in the management of chronic coronary syndromes: A strategy to improve treatment adherence and patient outcomes?

https://doi.org/10.1016/j.ijcard.2023.04.046Get rights and content
Under a Creative Commons license
open access

Highlights

  • CCS represents a major management challenge, mainly in patients with comorbidities.

  • Single-pill combination (SPC) has the potential to improve treatment adherence in CCS.

  • SPCs allow modification of dosing when necessary.

  • SPCs combine agents with complementary mechanisms of action.

  • SPCs help implementing secondary prevention strategies.

Abstract

Chronic coronary syndrome (CCS) represents a major challenge for physicians, particularly in the context of an increasing aging population. Additionally, CCS is often underestimated and under-recognised, particularly in female patients. As patients are frequently affected by several chronic comorbidities requiring polypharmacy, this can have a negative impact on patients' adherence to treatment. To overcome this barrier, single-pill combination (SPC), or fixed-dose combination, therapies are already widely used in the management of conditions such as hypertension, dyslipidaemia, and diabetes mellitus. The use of SPC anti-anginal therapy deserves careful consideration, as it has the potential to substantially improve treatment adherence and clinical outcomes, along with reducing the failure of pharmacological treatment before considering other interventions in patients with CCS.

Keywords

Adherence
Angina
Chronic coronary syndrome
Comorbidities
Single-pill combination
Treatment

Data availability

The data underlying this article are available in PubMed at https://pubmed.ncbi.nlm.nih.gov.

Cited by (0)

1

Joint first authors.

2

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.